2. DES arena THE CURRENT APPROACH TO DES MARKET IS BASED ON DRUG
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA

3. Chemical union with a monomer of Triflusal
Active APPROACH IS LEVERAGED
Paclitaxel
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
P5 – Acrylic Polymer
Chemical union with a monomer of Triflusal

4. Chemical union with a monomer of Triflusal
Active APPROACH IS LEVERAGED
Simvastatin
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
P5 – Acrylic Polymer
Chemical union with a monomer of Triflusal

5. PLATFORM APOLO 3 STENT STENT APOLO3 Stainless Steel
Open Cell Structure
Diameters 3,00-4,50mm
High Uniform Radial Force
Superior Flexibility
Low Recoil (1%)
Good trackability
5F Guiding Catheter
Stainless Steel
Open Cell Structure
Diameters 2,00-2,75mm
High Uniform Radial Force
Superior Flexibility
Low Recoil (1%)
Good trackability
5F Guiding Catheter
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA

6. PLATFORM APOLO 3 STENT STENT APOLO3 - WIDTH Superior Flexibility
0,0045”
0,0041”
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
0,0033”
0,0033”
0,0049”
0,0045”
Superior Flexibility
Entry Profile 0,017’’

7. PLATFORM APOLO 3 STENT STENT APOLO3 – STRUT THICKNESS
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
0,0045”
0,0037”
Strut Thickness: ”
Excellent Crossing Profile
(0.038” - 0,041’’)
Strut Thickness: ”
Excellent Crossing Profile
(0.034” - 0,038’’)

8. PLATFORM APOLO 3 STENT STENT APOLO3 – CROWNS AND CONNECTORS 6 Crowns
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
6 Crowns
3 Connectors in spiral shape
Superior flexibility
High Uniform Radial Force
Low Recoil (1%)

9. PLATFORM APOLO 3 STENT STENT APOLO3 – CROWNS AND CONNECTORS 5 Crowns
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
5 Crowns
2 Connectors in spiral shape
Superior flexibility
High Uniform Radial Force
Low Recoil (1%)

10. PLATFORM
APOLO 3 STENT
PHYSICO-MECHANICAL PROPERTIES (COATING)
SMOOTHNESS
Propiedades físico-mecánicas (recubrimiento): traduïr!!
No turbulence
No roughness
No friction
Pre-crimping
Post-crimping
The Polymer is fixed to the stent thanks to a unique and proprietary Iberhospitex-Cordynamic process

11. PLATFORM APOLO 3 STENT PHYSICO-MECHANICAL PROPERTIES (COATING)
NO CRACK-BRIDGING
Propiedades físico-mecánicas (recubrimiento): traduïr!! A B
No modification of mechanical integrity
Surface protection
Non crackable

12. PLATFORM APOLO 3 STENT PHYSICO-MECHANICAL PROPERTIES (COATING)
NO STICKY
traduïr B
Easy balloon withdrawal
Non fragment detachment
Drug release homogeneity

13. Chemical union with a monomer of Triflusal
IRIST APPROACH IS LEVERAGED
Simvastatin
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
P5 – Acrylic Polymer
Chemical union with a monomer of Triflusal

14. Copolymer of methacrylic monomer containing Triflusal
& butyl acrylate
High molecular weight
High hydrolytic stability
Good drug loading
High biocompatibility
Biostable
Antiplatelet
Anti-inflammatory
The Polymer is patented and developed for DES applications by a co-development between Laboratorios Uriach and Iberhospitex-Cordynamic

15. POLYMER P-5 BIOSTABLE Triflusal Release % HTB Released Days
Traduir quadre HTB liberado
% HTB Released
Days

16. Compatibility of P-5 Polymer with different drugs
GOOD DRUG SUPPORT
Compatibility of P-5 Polymer with different drugs
Traduïr i disenyar quadre
% Drug % Polymer

17. POLYMER P-5 BIOLOGICAL PROPERTIES OF TRIFLUSAL NON PLATELET ADHESION
Si es creu oportú arreglar fotos
Control: Pre-incubation with
Platelet-rich plasma
Control: Post-incubation with
Platelet-rich plasma
Control: Post-incubation with
Platelet-rich plasma
Polymer P-5: Pre-incubation
With platelet-rich plasma
Polymer P-5: Pre-incubation
With platelet-rich plasma
Polymer P-5: Post-incubation
With platelet-rich plasma
Polymer P-5: Post-incubation
With platelet-rich plasma

18. POLYMER P-5 BIOCOMPATIBLE: OSTEOBLASTS AND FIBROBLASTS
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE: OSTEOBLASTS AND FIBROBLASTS
Control
Polymer P-5
Normal cell adhesion
Standard cell growing
Normal morphology

19. Polímer Pattern (Cordis) Polímer Pattern (Cordis)
POLYMER
P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE: EX-VIVO PLATELET DEPOSITION (Badimon’s Camera)
Camera diameter: 0.2cm
212/s
DacrOn 10 20 30 40 *
p<0.05 vs Dacron
Platelet Adhesion
(x10 6
/cm 2 )
Polímer Pattern (Cordis)
Active’s polymer
Camera diameter: 0.1cm
1690/s 10 20 30 40 *
Platelet Adhesion
(x10 6
/cm 2 )
DacrOn
p<0.05 vs Dacron
Polímer Pattern (Cordis)
Active’s polymer
Non thrombogenic
Source: Catalan Institute of Cardiovascular Sciences (Barcelona)

20. Polímer Pattern (Cordis) Polímer Pattern (Cordis)
POLYMER
P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE: IN-VITRO PLATELET ADHESION (Static Conditions)
HEPARINE *
* P<0.05 vs Cordis
Dacron
Polímer Pattern (Cordis)
Active’s polymer
5.00
5.25
5.50
5.75
6.00
Platelet Adhesion
(x10 6
/cm 2 ) *
Dacron
Active’s polymer
2.00
2.25
2.50
2.75
3.00
Platelet Adhesion
(x10 6
/cm 2 )
CITRATE
Polímer Pattern (Cordis)
Non thrombogenic
Source: Catalan Institute of Cardiovascular Sciences (Barcelona)

21. Chemical union with a monomer of Triflusal
ACTIVE APPROACH IS LEVERAGED
Paclitaxel
Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA
I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA
P5 – Acrylic Polymer
Chemical union with a monomer of Triflusal

22. Paclitaxel - Effective anti-proliferative drug
Numerous studies demonstrated the positive effects of Paclitaxel on inhibiting Smooth Muscle Cell (SMC) proliferation and migration.
Paclitaxel supports an uniform drug distribution and suppresses the formation of neointimal hyperplasia due to its lipophilic property.

23. DRUG:
PACLITAXEL